Bian L - Search Results

1

Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.

Bian L, Wang T, Zhang S, Jiang Z. Bian L, et al. Tumour Biol. 2013 Oct;34(5):3153-8. doi: 10.1007/s13277-013-0884-y. Epub 2013 Jun 1. Tumour Biol. 2013. PMID: 23729232 Clinical Trial.

2

[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].

Huang HY, Jiang ZF, Wang T, Zhang SH, Bian L, Cao Y, Wu SK, Song ST. Huang HY, et al. Among authors: bian l. Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):850-3. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22335952 Chinese.

3

Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.

Huang H, Jiang Z, Wang T, Zhang S, Bian L, Cao Y, Wu S, Song S. Huang H, et al. Among authors: bian l. Anticancer Drugs. 2012 Aug;23(7):718-23. doi: 10.1097/CAD.0b013e328351802e. Anticancer Drugs. 2012. PMID: 22739713 Clinical Trial.

4

Evaluation of treatment response for breast cancer: are we entering the era of "biological complete remission"?

Bian L, Wang T, Liu Y, Zhang HQ, Song JJ, Zhang SH, Wu SK, Song ST, Jiang ZF. Bian L, et al. Chin J Cancer Res. 2012 Dec;24(4):403-7. doi: 10.3978/j.issn.1000-9604.2012.11.01. Chin J Cancer Res. 2012. PMID: 23359646 Free PMC article.

5

[Efficacy and prognostic analysis of retreatment with trastuzumab-based therapy after multi-line targeted therapy resistance in HER2-positive metastatic breast cancer].

Bian L, Jiang ZF, Wang T, Song JJ, Guo YF, Zhang HQ, Zhang SH, Wu SK, Song ST. Bian L, et al. Zhonghua Yi Xue Za Zhi. 2013 Jan 1;93(1):48-52. Zhonghua Yi Xue Za Zhi. 2013. PMID: 23578455 Chinese.

6

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.

Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu H, Li S, Hu Z, Wu S, Liu B, Jiang Z. Liu Y, et al. Among authors: bian l. BMC Cancer. 2013 Apr 23;13:202. doi: 10.1186/1471-2407-13-202. BMC Cancer. 2013. PMID: 23617715 Free PMC article.

7

Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab.

Bian L, Wang T, Zhang SH, Zhang HQ, Guo YF, Du G, Li W, Wu SK, Song ST, Jiang ZF. Bian L, et al. Cancer Biol Ther. 2014 Apr;15(4):365-70. doi: 10.4161/cbt.27624. Epub 2014 Jan 14. Cancer Biol Ther. 2014. PMID: 24424115 Free PMC article.

8

[Prediction value for dynamic changes of circulating tumor cell in therapeutic response and prognosis of Chinese metastatic breast cancer patients].

Bian L, Liu Y, Wang T, Zhang S, Shao Z, Tong Z, Song E, Wang X, Liao N, Jiang Z. Bian L, et al. Zhonghua Yi Xue Za Zhi. 2014 Jan 28;94(4):265-8. Zhonghua Yi Xue Za Zhi. 2014. PMID: 24731491 Clinical Trial. Chinese.

9

[Detection of circulating tumor cells and its clinical value for different stages and various subtypes of breast cancer].

Li L, Liu Y, Zhang S, Wang T, Bian L, Wu S, Song S, Liu B, Jiang Z. Li L, et al. Among authors: bian l. Zhonghua Yi Xue Za Zhi. 2014 Sep 30;94(36):2812-5. Zhonghua Yi Xue Za Zhi. 2014. PMID: 25534097 Chinese.

10

[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance].

Du G, Bian L, Wang T, Xu X, Zhang S, Guo Y, Zhuo J, Song S, Jiang Z. Du G, et al. Among authors: bian l. Zhonghua Yi Xue Za Zhi. 2015 Jul 28;95(28):2264-7. Zhonghua Yi Xue Za Zhi. 2015. PMID: 26710948 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,388 results

Search Page

Filters